prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype Her2, F. Pathologic Interpretation: A. Right axilla: - Micrometastatic carcinoma in one out of six lymph nodes (1/6). - Size of metastatic deposit: 1.25mm. - Note: Immunohistochemistry for keratin was used for interpretation. B. Right lumpectomy: - Invasive. poorly differentiated ductal carcinoma, high nuclear grade, 1.5 cm in greatest dimension. - Invasive carcinoma is present at less than 1 mm from the inferior margin. - Ductal carcinoma in situ is present within 1 mm of lateral and inferior margins. - Lymphovascular space invasion is identified. - Previous biopsy site. - See Tumor Summary. Tumor Summary: Specimen Type: Right lumpectomy. Procedure: Excision with wire-guided localization. Lymph Node Sampling: Sentinel lymph nodes. Specimen integrity: Single intact specimen. Specimen Size: - Greatest dimension: 8.9 cm. - Additional dimensions: 8.2 x 2.3 cm. Laterality: Right. Tumor Size: - Greatest dimension of largest focus of invasion over 0.1 cm: 2.5 cm. - Additional dimensions: 2.2 x 1.2 cm. Tumor Focality: Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of Tumor: Skin: Invasive carcinoma does not invade into the dermis or epidermis. Skeletal Muscle: No skeletal muscle present. Histologic Type: Invasive ductal carcinoma. Histologic Grade: - Glandular (Acinar)/Tubular Differentiation: Score 3: <10% of tumor area forming glandular/tubular structures. Nuclear Pleomorphism: Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation. In size and. shape, occasionally with very large and bizarre forms. Mitotic count: Score 1. Overall Grade: Grade 2: Score of 6 or 7. Margins: Margins uninvolved by invasive carcinoma. Distance from closest margin: < 1 mm (inferior). Specify margins: Distance from superior margin: 10 mm. Distance from inferior margin: < 1 mm. Distance from anterior margin ;> 10 mm. Distance from posterior margin: < 2 mm. Distance from medial margin ;> 10 mm. Distance from lateral margin: > 10 mm. Margins: uninvolved by DCIS: Distance from closest margin: < 1 mm (inferior, lateral). Treatment Effect: Response to Presurgical (neoadjuvant): Therapy: No known Presurgical therapy. Lymph-Vascular Invasion: Present. Dermal Lymph-Vascular Invasion: Not identified. Lymph Nodes: SURGICAL PATHOL Report. Number of sentinel nodes examined: 6. Total number of nodes examined (sentinel and Nonsentinel): 6. Number of lymph nodes with macrometastases (>0.2 cm): 0. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or>200 cells): 1. Number of lymph nodes with isolated tumor cells (<0.2 mm and <200 cells): 0. Size of largest metastatic deposit: .25mm. Extranodal Extension: Not identified. Method of evaluation of Sentinel Lymph Nodes: - Hematoxylin and eosin (H&E), one level. - Immunohistochemistry. Pathologic Staging (pTNM): pT2, pN1mi, pM (not applicable). Regional Lymph Nodes (pN): pN1mi. Anciliary Studies: To Follow. used: NOTE: IIS-ER Some PgR 636-PR,A485-HER2, H-11-EGFR. are analyte All specific reagents (ASRs) validated are used by with our formalin laboratory. or molecular These ASRs frred. are paraffin climcally emheudded indicators tisse. Detection that do not is by require Envision FDA Methnd approval The These esults clones are read are by a. pathologist as positive or negritive. As the attending pathologist, 1 attest that I: (i) Examined the relevant preparatton(s). for the specimen(s); and (ii) Rendered the diagnosis(es). MD. Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. A. Right axilla: - The tumor cells are negative for ER, PR and Her-2 by Immunohistochemistry. - The tumor cells are also negative for E-cadherin. - This immunophenotype may be seen in the basal subtype of mammary carcinoma. - Additional Immunohistochemistry to follow. :, MD. Addendum. Date Complete: Addendum Diagnosis. B. Right lumpectomy one suture superior, two medial: SURGICAL PATHOL Report. - The tumor cells are positive for p-cadherin and negative for CK5/6 and EGFR by Immunohistochemistry. MD. Intraoperative Consultation. Right axilla, FS: 3 lymph nodes: no tumor on frozen section. Await sentinel node protocol for definitive diagnosis. MD. Clinical History: Patient with biopsy proven G3 cancer right breast. i for needle localization segmental mastectomy with SLNB. Please. evaluate sentinal nodes for metastasis and do Immunohistochemistry on permanents if frozen negative, evaluate lumpectomy. margins. Operation Performed. Right needle localization mastectomy with SLNB, possible AND, right lumpectomy. Pre Operative Diagnosis: Cancer right breast. Specimen(s) Received: A: Right axilla fs. B: Right lumpectomy one suture superior, two medial. Gross Description: A. Received fresh for frozen section is an irregular fragment of fibroadipose tissue, measuring 3.2 x 2.0 x 1.1 cn. Seven. lymph nodes are identified at the time of consultation. In the rest of the adipose tissue two possible lymph nodes are. identified. The fragments are submitted in toto as follows: 1-3. One lymph node per cassette for frozen section. 4&5. One additional lymph node per cassette. 6&7. The rest of the fibroadipose tissue. B. Received in formalin is a lumpectomy specimen, measuring 8.9 cm from medial to lateral, 8.2 cm from anterior to. posterior, 2.3 cm in from superior to inferior. A metallic localization needle is located in the anterior aspect of the. specimen. Surgical margins are inked as follows: superior inked blue, inferior inked green, medial inked red, fateral inked. orange, anterior inked yellow, posterior inked black. Upon sectioning at the tip of the needle localization an irregular firm,. tan and white area is identified, measuring, 2.5 x 2.2 x 1.2 cm. This area is up to, 0.1 cm from the inferior margin, 1.5 cm. from the deep posterior margin, 4.5 cm from the anterior margin, 2.3 cm from the lateral margin, 1.0 cm from the superior. margin, 3.2 cm from the medial margin. Representative section of the tumor is submitted for tissue bank. Other areas of. the. specimen are fibroadipose with a stroma to fat ratio of 10:90. Representative sections are submitted as follows: 1&2. Sections of the tumor in relation with the inferior and superior margins. 3. Tumor in relation with the deep margin. 4&5. Additional sections (composite) of the tumor in relation with the inferior and deep margins. 6. Lateral margin. 7. Medial margin. 8. Anterior margin. 9-11. Additional sections of the tumor. ..3.

expanded version (tokens=2071) : 
 Histological classification: Invasive poorly differentiated ductal carcinoma, high nuclear grade. Presence of Ductal carcinoma in situ (DCIS) and metastatic carcinoma in 1/6 lymph nodes.

Subtype: HER2 positive

Description of any necrosis: No mention of necrosis in the report.

Tumor infiltrating lymphocytes: Mention of lymphovascular invasion is made but no specific information on tumor infiltrating lymphocytes is given.

Histological grade: Glandular/Tubular differentiation score of 3 (<10% of tumor area forming glandular/tubular structures), Nuclear Pleomorphism score of 3 (Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms) and mitotic count score of 1. Overall Grade 2 (score of 6 or 7).

Nuclear grade: High nuclear grade.

Lymphovascular invasion: Identified.

Calcification: No mention of calcification in the report.

Receptor status: ER, PR, and Her-2 receptors are mentioned in the addendum. The tumor cells are negative for ER, PR and Her-2 by Immunohistochemistry. 

IHC and any other ancillary testing results: Additional immunohistochemistry to follow. Tumor cells are also negative for E-cadherin. The tumor cells are positive for p-cadherin and negative for CK5/6 and EGFR. No anc

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2239) : 
 The pathology report showed invasive poorly differentiated ductal carcinoma, high nuclear grade, with presence of ductal carcinoma in situ (DCIS) and lymphovascular invasion. HER2 positive subtype was detected, and one out of six lymph nodes showed micrometastatic carcinoma. The tumor cells were negative for ER, PR and Her-2 by immunohistochemistry with additional immunohistochemistry to follow. Nuclear pleomorphism score was 3 with an overall grade of 2. The tumor cells are positive for p-cadherin and negative for CK5/6 and EGFR.

